Kantonsspital Graubünden

PUBLIKATIONEN

Prof. Dr. med. Thomas Fehr

Original papers

1) **Fehr,T.**, Bachmann,M.F., Bluethmann,H., Kikutani,H., Hengartner,H., & Zinkernagel,R.M. T-independent activation of B cells by vesicular stomatitis virus: no evidence for the need of a second signal. *Cell. Immunol.* 168, 184-192 (1996).

2) Holtschke,T., Löhler,J., Kanno,Y., **Fehr,T.**, Giese,N., Rosenbauer,F., Lou,J., Knobeloch,K.-P., Gabriele,L., Waring,J.F., Bachmann,M.F., Zinkernagel,R.M., Morse III,H.C., Ozato,K., & Horak,I. Immunodeficiency and chronic myelogenous leukemia - like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* 87, 307-317 (1996).

3) Bachmann,M.F., Lutz,M.B., Layton,G.T., Harris,S.J., **Fehr,T.**, Hengartner,H., Zinkernagel,R.M., & RicciardiCastagnoli,P. Dendritic cells process exogenous viral proteins and virus-like particles for MHC class I presentation to CD8+ cytotoxic T lymphocytes. *Eur. J Immunol.* 26, 2595-2600 (1996).

4) **Fehr,T.**, Bachmann,M.F., Bucher,E., Kalinke,U., Di Padova,F.E., Lang,A.B., Hengartner,H., & Zinkernagel,R.M. Role of repetitive antigen patterns for induction of antibodies against antibodies. *J. Exp. Med.* 185, 1785-1792 (1997).

5) Bachmann,M.F., **Fehr,T.**, Freer,G., Hengartner,H., & Zinkernagel,R.M. Correlation of tolerogenicity of a viral antigen with its immunogenicity. *J. Immunol.* 158, 5106-5111 (1997).

6) **Fehr,T.**, Schoedon,G., Odermatt,B., Holtschke,T., Schneemann,M., Bachmann,M.F., Mak,T.W., Horak,I., & Zinkernagel,R.M. Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis. *J. Exp. Med.* 185, 921-931 (1997).

7) Tourne,S., Miyazaki,T., Oxenius,A., Klein,L., **Fehr,T.**, Kyewski,B., Benoist,C., & Mathis,D. Selection of a broad repertoire of CD4+ T cells in H-2Ma0/0 mice. *Immunity* 7, 187-195 (1997).

8) **Fehr,T.**, Naim,H.Y., Bachmann,M.F., Ochsenbein,A.F., Spielhofer,P., Bucher,E., Hengartner,H., Billeter,M.A., & Zinkernagel,R.M. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. *Nat. Med.* 4, 945-948 (1998).

9) **Fehr,T.**, Skrastina,D., Pumpens,P., & Zinkernagel,R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. *Proc. Natl. Acad. Sci. U. S. A.* 95, 9477-9481 (1998).

10) **Fehr,T.**, Rickert,R.C., Odermatt,B., Roes,J., Rajewsky,K., Hengartner,H., & Zinkernagel,R.M. Antiviral protection and germinal center formation, but impaired B cell memory in the absence of CD19. *J Exp. Med.* 188, 145-155 (1998).

11) Spielhofer,P., Bächi,T., **Fehr,T.**, Christiansen,G., Cattaneo,R., Kaelin,K., Billeter,M.A., & Naim,H.Y. Chimeric

measles viruses with a foreign envelope. *J Virol.* 72, 2150-2159 (1998).

12) Ochsenbein,A.F., **Fehr,T.**, Lutz,C., Suter,M., Brombacher,F., Hengartner,H., & Zinkernagel,R.M. Control of early viral and bacterial distribution and disease by natural antibodies. *Science* 286, 2156-2159 (1999).

13) **Fehr,T.**, Lopez-Macias,C., Odermatt,B., Torres,R.M., Schubart,D.B., O'Keefe,T.L., Matthias,P., Hengartner,H., & Zinkernagel,R.M. Correlation of anti-viral B cell responses and splenic morphology with expression of B cell-specific molecules. *Int. Immunol.* 12, 1275-1284 (2000).

14) Pinschewer,D.D., Ochsenbein,A.F., **Fehr,T.**, & Zinkernagel,R.M. Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine. *Transplantation* 72, 712-719 (2001).

15) Ammann,P., **Fehr,T.**, Minder,E.I., Gunter,C., & Bertel,O. Elevation of troponin I in sepsis and septic shock. *Intensive Care Med.* 27, 965-969 (2001).

16) **Fehr,T.**, Bossart,W., Wahl,C., & Binswanger,U. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. *Transplantation* 73, 608-611 (2002).

17) **Fehr**,T., Knoflach,A., Ammann,P., Pei,P., & Binswanger,U. Differential use of cardiac troponin T versus I in hemodialysis patients. *Clin. Nephrol.* 59, 35-39 (2003).

18) Ammann,P., Maggiorini,M., Bertel,O., Haenseler,E., Joller-Jemelka,H.I., Oechslin,E., Minder,E.I., Rickli,H., & **Fehr**,T. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. *J. Am. Coll. Cardiol.* 41, 2004-2009 (2003).

19) **Fehr**,T., Riehle,H.M., Nigg,L., Gruter,E., Ammann,P., Renner,E.L., & Ambuhl,P.M. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. *Am. J. Kidney Dis.* 42, 193-201 (2003).

20) Rickli,H., Benou,K., Ammann,P., **Fehr**,T., Brunner-La Rocca,H.P., Petridis,H., Riesen,W., & Wuthrich,R.P. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. *Clin. Nephrol.* 61, 98-102 (2004).

21) Ammann,P., Brunner-La Rocca,H., **Fehr**,T., Munzer,T., Sagmeister,M., Angehrn,W., & Rickli,H. Coronary anatomy and left ventricular ejection fraction in patients with type 2 diabetes admitted for elective coronary angiography. *Catheter. Cardiovasc. Interv.* 62, 432-438 (2004).

22) **Fehr**,T., Kahlert,C., Fierz,W., Joller-Jemelka,H.I., Riesen,W.F., Rickli,H., Wuthrich,R.P., & Ammann,P. Statininduced immunomodulatory effects on human T cells in vivo. *Atherosclerosis* 175, 83-90 (2004).

23) **Fehr**,T., Ammann,P., Garzoni,D., Korte,W., Fierz,W., Rickli,H., & Wuthrich,R.P. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. *Kidney Int.* 66, 1206-1211 (2004)

24) **Fehr**,T., Takeuchi,Y., Kurtz,J., Wekerle,T. & Sykes,M. Early regulation of CD8 T cell alloreactivity by CD4(+)CD25(-) T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8(+) T cells, precluding a role for sustained regulation. *Eur J Immunol.* 35, :2679-2690 (2005)

25) Fudaba,Y., Spitzer,T.R., Shaffer,J., Kawai,T., **Fehr**,T., Delmonico,F., Preffer,F., Tolkoff-Rubin,N., Dey,B., Saidman,S.L., Kraus,A., Bonnefoix,T., McAfee,S., Power,K., Kattleman,K., Colvin,R.B., Sachs,D.H., Cosimi,A.B., Sykes,M. Myeloma responses and tolerance following combined kidney and non-myeloablative marrow transplantation: in vivo and in vitro analyses. *Am J Transplant.* 6, 2121-2133 (2006)

26) **Fehr**,T., Garzoni,D.,Staub,T.,Binet,I. & Wuthrich,R.P. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients. *Kidney Blood Press Res.* 29, 175-181 (2006).

27) Spanou Z, Keller M, Britschgi M, Yawalkar N, **Fehr** T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ. Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. *J Am Soc Nephrol.* 17:2919-2927 (2006).

28) Nigg-Calanca L, **Fehr** T, Jochum W, Fischer-Vetter J, Mullhaupt B, Wuthrich RP, Ambuhl PM. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. *J Clin Virol.* 39:54-58 (2007)

29) Yung GP, Valli PV, Starke A, Mueller RJ, **Fehr** T, Cesar-Ozpamir M, Schanz U, Weber M, Wüthrich RP, Seebach JD, Stussi G. Flow cytometric measurement of ABO antibodies in ABO-incompatible living donor kidney transplantation. *Transplantation 84(12 Suppl)*:S20-23 (2007).

30) Haspot F, **Fehr** T, Gibbons C, Zhao G, Hogan T, Honjo T, Freeman G, Sykes M. Peripheral deletional tolerance of alloreactive CD8, but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. *Blood.* 112:2149-2155 (2008)

31) **Fehr** T, Haspot F, Mollov J, Chittenden M, Hogan T, Sykes M. Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells and MHC class II. *J Immunol.* 181:165-173 (2008)

32) Henz S, Maeder M, Huber S, Schmid M, Loher M, **Fehr** T. Influence of Drugs and Comorbidity on Serum Potassium in 15'000 Consecutive Hospital Admissions. *Nephrol Dial Transplant.* 23:3939-3945 (2008)

33) **Fehr** T, Wang S, Haspot F, Kurtz J, Blaha P, Hogan T, Chittenden, Wekerle T, Sykes M. Rapid, deletional peripheral CD8 T cell tolerance induced by allogeneic bone marrow: role of donor class II MHC and B cells. *J Immunol.* 181:4371-4380 (2008)

34) Valli PV, Puga Yung G, Schulz-Huotari C, Kaup N, Güngör T, Ambühl PM, Weber M, **Fehr** T, Schanz U, Seebach JD, Stussi G. Changes of circulating antibody levels induced by ABO antibody absorption for ABO Incompatible Kidney Transplantation. *Am J Transplant.* 9:1072-1080 (2009)

35) **Fehr** T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment for chronic antibody-mediated kidney allograft rejection. *Transplantation* 87:1837-1841 (2009).

36) Grimmelt AC, Cohen CD, **Fehr** T, Serra AL, Wuethrich RP. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. *ClinNephrol.* 71:125-9 (2009).

37) Gianella S, Haeberli L, Joos B, Ledergerber B, Wüthrich RP, Weber R, Kuster H, Hauser PM, **Fehr** T, Mueller NJ. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. *Transpl Infect Dis.* 12:1-10 (2010).

38) Neusser MA, Kraus AK, Regele H, Cohen CD, **Fehr** T, Kerjaschki D, Wüthrich RP, Penfold ME, Schall T, Segerer S. The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection. *Kid Int* 77:801-808 (2010).

39) Starke A, Lindenmeyer MT, Segerer S, Neusser MA, Rüsi B, Schmid DM, Cohen CD, Wüthrich RP, **Fehr** T, Waeckerle-Men Y. Renal tubular PD-L1 (CD274) suppresses alloreactive human T cell responses. *Kid Int* 78:38-47 (2010).

40) **Fehr** T, Lucas CL, Kurtz J, Onoe T, Zhao G, Hogan T, Vallot C, Rao A, Sykes M. A CD8 T cell-intrinsic role for the calcineurin-NFAT pathway for tolerance induction in vivo. *Blood* 115:1280-1287 (2010).

41) Altmann DR, Korte W, Maeder MT, **Fehr** T, Haager P, Rickli H, Kleger GR, Rodriguez R, Ammann P. Elevated cardiac troponin I in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis. *PLoS ONE* 5 (e9017):1-5 (2010).

42) Oettl T, Zuliani E, Gasper A, Hopfer H, Dickenmann M, **Fehr** T. Late steroid withdrawal after AB0 blood groupincompatible living donor kidney transplantation: high rate of mild cellular rejection. *Transplantation* 27;89(6):702-6 (2010).

43) Schorn R, Höhne M, Meerbach A, Bossart W, Wüthrich RP, Schreier E, Müller NJ, **Fehr** T. Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution. *Clin Inf Dis* 51:307-314 (2010).

44) Riethmüller S, Ferrari-Lacraz S, Müller MK, Raptis DA, Hadaya K, Rüsi B, Laube G, Schneiter G, **Fehr** T, Villard J. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. *Transplantation* 90: 160-167 (2010)

45) Fries C, Roos M, Gaspert A, Vogt P, Salomon F, Wüthrich RP, Vavricka SR, **Fehr** T. Atheroembolic disease - a frequently missed diagnosis: results of a 12-year matched-pair autopsy study. *Medicine (Baltimore)* 89:126-32 (2010).

46) Tian Y, Chen J, Gaspert A, Segerer S, Clavien PA, Wüthrich RP, **Fehr T.** Kidney transplantation in mice using left and right kidney grafts. *J Surg Res* 163: e91-7 (2010)

47) Lehmann K, Müller MK, Schiesser M, Wildi S, **Fehr** T, Wüthrich RP, Clavien PA, Weber M. Treatment of ureteral complications after kidney transplantation with native ureteropyelostomy reduces the risk of pyelonephritis. *Clin Transplant 2*5: 201-6 (2011).

48) Cippà PE, Kraus AK, Edenhofer I, Segerer S, Chen J, Hausmann M, Liu Y, Guimezanes A, Bardwell PD, Wüthrich RP, **Fehr T.** The BH3-mimetic ABT-737 inhibits allogeneic immune responses. *Transpl Int* 24: 722-32 (2011)

49) Fritzsche FR, Pianca S, Gaspert A, Varga Z, Wang L, Farrell MP, Chen XB, Hirsch HH, Springer E, **Fehr T**, Myles J, Tubbs R, Moch H. Silver-enhanced in situ hybridization for detection of polyomavirus DNA in patients with BK virus nephropathy. *Diagn Mol Pathol* 20:105-10 (2011)

50) Sullivan M, Rybicki LA, Winter A, Hoffmann MM, Reiermann S, Linke H, Arbeiter K, Patzer L, Budde K, Hoppe B, Zeier M, Lhotta K, Bock A, Wiech T, Gaspert A, **Fehr T**, Woznowski M, Berisha G, Malinoc A, Goek ON, Eng C, Neumann HP. Age-Related Penetrance of Hereditary Atypical Hemolytic Uremic Syndrome. *Ann Hum Genet.* 75: 639-647 (2011)

51) Schmid-Mohler G, Albiez T, Schäfer-Keller P, **Fehr T**, Biotti B, Spirig R. [In-patient education after renal transplantation]. *Pflege* 24: 317-28 (2011).

52) Wahrmann M, Schiemann M, Marinova L, Körmöczi GF, Derfler K, **Fehr T,** Stussi G, Böhmig GA. Anti-A/B antibody depletion by semiselective versus ABO blood group-specific immunoadsorption. *Nephrol Dial Transplant.* 27(5):2122-92 (2012)

53) Varga Z, Gaspert A, Behnke S, von Teichman A, Fritzsche F, **Fehr T.** Tubular and endothelial chimerism in renal allografts using fluorescence and chromogenic in situ hybridization (FISH, CISH) technology. *Pathol Int.* 62: 254-63 (2012)

54) Sassi M, Ripamonti C, Mueller NJ, Yazaki H, Kutty G, Ma L, Huber C, Gogineni E, Oka S, Goto N, **Fehr T,** Gianella S, Konrad R, Sing A, Kovacs JA. Outbreaks of pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of pneumocystis: implications for transmission and virulence. *Clin Infect Dis.* 54: 1437-44 (2012)

55) Cippà PE, Kraus AK, Lindenmeyer MT, Chen J, Guimezanes A, Bardwell PD, Wekerle T, Wüthrich RP, **Fehr T.** Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway. *Cell Death Dis.* 19; 3:e299 (2012)

56) Maeder MT, Rickli H, Pfisterer ME, Muzzarelli S, Ammann P, **Fehr T,** Hack D, Weilenmann D, Dieterle T, Kiencke S, Estlinbaum W, Brunner-La Rocca HP; TIME-CHF Investigators. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. *Am Heart J.* 163: 407-14 (2012)

57) Greiner M, Cusini A, Ruesch M, Schiesser M, Ledergerber B, **Fehr T,** Mueller NJ. A stringent preemptive protocol reduces cytomegalovirus disease in the first 6 months after kidney transplantation. *Infection.* 40(6):669-75 (2012)

58) Varga Z, Gaspert A, Behnke S, von Teichman A, Fritzsche F, **Fehr T.** Tubular and endothelial chimerism in renal allografts using fluorescence and chromogenic in situ hybridization (FISH, CISH) technology. *Pathol Int.* 62(4):254-63 (2012).

59) Sassi M, Ripamonti C, Mueller NJ, Yazaki H, Kutty G, Ma L, Huber C, Gogineni E, Oka S, Goto N, **Fehr T,** Gianella S, Konrad R, Sing A, Kovacs JA. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. *Clin Infect Dis.* 54(10):1437-44 (2012)

60) Schmid-Mohler G, **Fehr T,** Witschi P, Albiez T, Biotti B, Spirig R. [Development of an evidence-based selfmanagement programme for patients in the first year after renal transplantation with a focus on prevention of weight gain, physical exercise and drug adherence]. *Pflege* 26(3):191-205 (2013).

61) Koller MT, van Delden C, Müller NJ, Baumann P, Lovis C, Marti HP, **Fehr T,** Binet I, De Geest S, Bucher HC, Meylan P, Pascual M, Steiger J. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. *Eur J Epidemiol.* 28(4):347-55 (2013).

62) Kraus AK, Cippá PE, Gaspert A, Chen J, Edenhofer I, Wüthrich RP, Lindenmeyer M, Segerer S, **Fehr T.** Absence of donor CD40 protects renal allograft epithelium and preserves renal function. *Transpl Int.* (5):535-44 (2013)

63) Cippà PE, Kamarashev J, Chen J, Kraus AK, Segerer S, Feldmeyer L, **Fehr T.** Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A. *Apoptosis.* 18(3):315-23 (2013).

64) Cippà PE, Gabriel SS, Chen J, Bardwell PD, Bushell A, Guimezanes A, Kraus AK, Wekerle T, Wüthrich RP, **Fehr T.** Targeting apoptosis to induce stable mixed haematopoietic chimerism and long-term allograft survival without myelosuppressive conditioning in mice. *Blood.* 122: 1669-77 (2013)

65) Burkhalter H, Brunner DP, Wirz-Justice A, Cajochen C, Weaver TE, Steiger J, **Fehr T**, Venzin RM, De Geest S. Validation of a single item to assess daytime sleepiness for the Swiss Transplant Cohort Study. *Prog Transplant.* 23:220-8 (2013).

66) Burkhalter H, Brunner DP, Wirz-Justice A, Cajochen C, Weaver TE, Steiger J, **Fehr T**, Venzin RM, De Geest S. Self-reported sleep disturbances in renal transplant recipients. *BMC Nephrol.* 14: 220 (2013).

67) Raess M, Fröhlich G, Roos M, Rüsi B, Wilhelm MJ, Noll G, Ruschitzka F, **Fehr T**, Enseleit F. Donor-specific antiHLA antibodies detected by Luminex: predictive for short-term but not long-term survival after heart transplantation. *Transpl Int.* 26: 1097-107 (2013).

68) Cippà PE, Gabriel SS, Kraus AK, Chen J, Wekerle T, Guimezanes A, Wüthrich RP, **Fehr T**. Bcl-2 inhibition to overcome memory cell barriers in transplantation. *Am J Transplant.* 14: 333-42 (2014)

69) Bucher C, Tapernoux D, Diethelm M, Büscher C, Noser A, **Fehr T**, Henz S. Influence of weather conditions, drugs and comorbidities on serum Na and Cl in 13000 hospital admissions: evidence for a subpopulation susceptible for SIADH. *Clin Biochem.* 47: 618-24 (2014)

70) Burkhalter H, Wirz-Justice A, Cajochen C, Weaver TE, Steiger J, **Fehr T**, Venzin RM, De Geest S. Daytime sleepiness in renal transplant recipients is associated with immunosuppressive non-adherence: a cross-sectional, multi-center study. *Clin Transplant.* 28: 58-66 (2014)

71) Haspot F, Li HW, Lucas CL, **Fehr T**, Beyaz S, Sykes M. Allospecific rejection of MHC class I-deficient bone marrow by CD8 T cells. *Am J Transplant.* 14: 19-58 (2014)

72) Hässig A, Roos M, Etter A, Bossart W, Müller N, Schiesser M, Wüthrich RP, **Fehr T.** Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor. *Transpl Infect Dis.* 16: 44-54 (2014).

73) Schmid-Mohler G, Schäfer-Keller P, Frei A, **Fehr T**, Spirig R. A mixed-method study to explore patients' perspective of self-management tasks in the early phase after kidney transplant. *Prog Transplant.* 24: 8-18 (2014).

74) Lo Cascio CM, Latshang TD, Kohler M, **Fehr T**, Bloch KE. Severe metabolic acidosis in adult patients with Duchenne muscular dystrophy. *Respiration.* 87: 499-503 (2014).

75) Bonani M, Rodriguez D, **Fehr T**, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wüthrich RP. Sclerostin blood levels before and after kidney transplantation. *Kidney Blood Press Res.* 39: 230-9 (2014)

76) Burkhalter H, Wirz-Justice A, Denhaerynck K, **Fehr T**, Steiger J, Venzin RM, Cajochen C, Weaver TE, De Geest S. The effect of bright light therapy on sleep and circadian rhythms in renal transplant recipients: a pilot randomized, multicentre wait-list controlled trial. *Transpl Int.* 28: 59-70 (2015)

77) Schiesser M, Steinemann DC, Hadaya K, Huyen-Do U, Eisenberger U, Binet I, **Fehr T**, Dickenmann M. The Reuse of Immunoadsorption Columns in ABO-Incompatible Kidney Transplantation Is Efficient: The Swiss Experience. *Transplantation.* 99: 1030-5 (2015)

78) Cippà PE, Schiesser M, Ekberg H, van Gelder T, Mueller NJ, Cao CA, **Fehr T**, Bernasconi C. Risk Stratification for Rejection and Infection after Kidney Transplantation. *Clin J Am Soc Nephrol.* 10: 2213-20 (2015).

79) Weitz M, Heeringa S, Neuhaus TJ, **Fehr T**, Laube GF. Standardized multilevel transition program: Does it affect renal transplant outcome? *Pediatr Transplant.* 19: 691-7 (2015)

80) Lehnhardt A, Karnatz C, Ahlenstiel-Grunow T, Benz K, Benz MR, Budde K, Büscher AK, **Fehr T**, Feldkötter M, Graf N, Höcker B, Jungraithmayr T, Klaus G, Koehler B, Konrad M, Kranz B, Montoya CR, Müller D, Neuhaus TJ, Oh J, Pape L, Pohl M, Royer-Pokora B, Querfeld U, Schneppenheim R, Staude H, Spartà G, Timmermann K, Wilkening F, Wygoda S, Bergmann C, Kemper MJ. Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1. *Clin J Am Soc Nephrol.* 10: 825-31 (2015)

81) Matter-Walstra KW, Greiner M, Cusini A, Schiesser M, Ledergerber B, **Fehr T**, Mueller NJ. Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. *Transpl Infect Dis.* 17: 342-9 (2015)

82) Süsal C, Wettstein D, Döhler B, Morath C, Ruhenstroth A, Scherer S, Tran TH, Gombos P, Schemmer P, Wagner E, **Fehr T**, Živčić-Ćosić S, Balen S, Weimer R, Slavcev A, Bösmüller C, Norman DJ, Zeier M, Opelz G; Collaborative Transplant Study Report. Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. *Transplantation.* 99: 1976-80 (2015).

83) Cippà PE, Grebe SO, **Fehr T,** Wüthrich RP, Mueller TF. Altitude and arteriolar hyalinosis after kidney transplantation. *Nephrology (Carlton).* 21:782-4 (2016)

84) Tapernoux D, Diethelm M, Bucher C, Propp S, **Fehr T,** Henz S. Influence of postmenopausal state, solar radiation, drugs and comorbidities on serum calcium and phosphate in 13,000 hospital admissions. *Clin Nephrol.* 85(6):309-15 (2016)

85) Gabriel SS, Bon N, Chen J, Wekerle T, Bushell A, **Fehr T,** Cippà PE. Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance. *Front Immunol.* 1;7:73 (2016)

86) Kraus AK, Chen J, Edenhofer I, Ravens I, Gaspert A, Cippà PE, Mueller S, Wuthrich RP, Segerer S, Bernhardt G, **Fehr T.** The Role of T Cell Costimulation via DNAM-1 in Kidney Transplantation. *PLoS One.* 11(2):e0147951 (2016).

87) Bonani M, Frey D, Brockmann J, **Fehr T,** Mueller TF, Saleh L, von Eckardstein A, Graf N, Wüthrich RP. Effect of Twice-Yearly Denosumab on Prevention of Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: A Randomized Controlled Trial. *Am J Transplant.* 16:1882-91 (2016).

88) Süsal C, Döhler B, Ruhenstroth A, Morath C, Slavcev A, **Fehr T,** Wagner E, Krüger B, Rees M, Balen S, Živčić-Ćosić S, Norman DJ, Kuypers D, Emonds MP, Pisarski P, Bösmüller C, Weimer R, Mytilineos J, Scherer S, Tran TH, Gombos P, Schemmer P, Zeier M, Opelz G; A Collaborative Transplant Study Report. Donor-specific antibodies require preactivated immune system to harm renal transplant. *EBioMedicine.* 9:366-371 (2016).

89) Bonani M, Pereira RM, Misselwitz B, **Fehr T,** Wüthrich RP, Franzen D. Chronic Norovirus Infection as a Risk Factor for Secondary Lactose Maldigestion in Renal Transplant Recipients: A Prospective Parallel Cohort Pilot Study. *Transplantation* 101(6):1455-1460 (2017)

90) Gabriel SS, Belge H, Gassama A, Debaix H, Luciani A, **Fehr T,** Devuyst O. Bone marrow transplantation improves proximal tubule dysfunction in a mouse model of Dent disease. *Kidney Int.* 91:842-855 (2017)

91) Seeger H, Lindenmeyer MT, Cohen CD, Jaeckel C, Nelson PJ, Chen J, Edenhofer I, Kozakowski N, Regele H, Boehmig G, Brandt S, Wuethrich RP, Heikenwalder M, **Fehr T,** Segerer S. Lymphotoxin expression in human and murine renal allografts. *PLoS One* 4;13(1):e0189396 (2018)

92) Stocker A, Theus C, Boggian K, Mueller NJ, Fleisch F, **Fehr T**. Hohe Inzidenz von Varizella- Zoster Meningoenzephalitiden in Graubünden im Jahr 2014. Praxis (Bern 1994) 107(7):363-371 (2018)

93) Gerber L, Gaspert A, Braghetti A, Zwahlen H, Wüthrich R, Zbinden R, Mueller N, **Fehr T.** Ureaplasma and Mycoplasma in kidney allograft recipients-A case series and review of the literature. *Transpl Infect Dis.* 20(5):e12937 (2018)

94) Weber NT, Bonani M, Benden C, Schleich A, **Fehr T,** Mueller TF, Schuurmans MM. Evolution of lung and kidney allograft function in patients receiving kidney after lung transplantation. *Clin Transplant* 32(2): e13169. (2018)

95) Steiner R, Kridel R, Giostra E, McKee T, Achermann R, Mueller N, Manuel O, Dickenmann M, Schuurmans MM, de Leval L, **Fehr T,** Tinguely M, Binet I, Cogliatti S, Haralamvieva E, Koller M, The Swiss Transplant Cohort Study Stcs, Dietrich PY. Low 5-year cumulative incidence of post-transplant lymphoproliferative disorders after solid organ transplantation in Switzerland. *Swiss Med Wkly* 8;148:w14596 (2018)

96) Schreiber PW, Bischoff-Ferrari HA, Boggian K, Bonani M, van Delden C, Enriquez N, **Fehr T,** Garzoni C, Hirsch HH, Hirzel C, Manuel O, Meylan P, Saleh L, Weisser M, Mueller NJ; Swiss Transplant Cohort Study (STCS). Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation. *PLoS One* 16;13(1):e0191167 (2018).

97) Schreiber PW, Bischoff-Ferrari HA, Boggian K, van Delden C, Enriquez N, **Fehr T,** Garzoni C, Hirsch HH, Hirzel C, Manuel O, Meylan P, Saleh L, Weisser M,Mueller NJ; Swiss Transplant Cohort Study (STCS). Vitamin D status and risk of infections after liver transplantation in the Swiss Transplant Cohort Study. *Transpl Int.* 32(1):49-58 (2019).

98) Schmid-Mohler G, Zala P, Graf N, Witschi P, Mueller TF, Peter Wüthrich R, Huber L, **Fehr T**, Spirig R. Comparison of a Behavioral Versus an Educational Weight Management Intervention After Renal Transplantation: A Randomized Controlled Trial. *Transplant Direct.* 5(12):e507 (2019).

99) Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, **Fehr T,** Rossi D, Bianchi E, Stüssi G, Ghilardi G, Gerber B. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. *Hematol Oncol.* 37(5):595-600 (2019).

100) Schreiber PW, Kusejko K, Bischoff-Ferrari HA, Boggian K, Bonani M, van Delden C, Enriquez N, **Fehr T,** Garzoni C, Hirsch HH, Hirzel C, Manuel O, Meylan P, Saleh L, Weisser M, Mueller NJ; Swiss Transplant Cohort Study (STCS). Vitamin D deficiency is common in kidney transplant recipients, but is not associated with infections after transplantation. *Clin Transplant.* 34(2):e13778 (2020).

101) Good-Weber M, Roos M, Mueller TF, Rüsi B, **Fehr T.** Tailored immunosuppression after kidney transplantation -a single center real-life experience. *BMC Nephrol.* 21(1):501 (2020).

102) Küchler L, **Fehr T**, Jeker R. Pain control with ibandronate for bone marrow oedema of the knee. *Swiss Med Wkly.* 150:w20384 (2020).

103) Bonani M, Achermann R, Seeger H, Scharfe M, Müller T, Schaub S, Binet I, Huynh-Do U, Dahdal S, Golshayan D, Hadaya K, Wüthrich RP, **Fehr T**, Segerer S. Dialysis after graft loss: a Swiss experience. *Nephrol Dial Transplant.* 35(12):2182-2190 (2020).

104) Olinger E, Hofmann P, Kidd K, Dufour I, Belge H, Schaeffer C, Kipp A, Bonny O, Deltas C, Demoulin N, **Fehr T,** Fuster DG, Gale DP, Goffin E, Hodaňová K, Huynh-Do U, Kistler A, Morelle J, Papagregoriou G, Pirson Y, Sandford R, Sayer JA, Torra R, Venzin C, Venzin R, Vogt B, Živná M, Greka A, Dahan K, Rampoldi L, Kmoch S, Bleyer AJ Sr, Devuyst O. Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease due to mutations in UMOD and MUC1. *Kidney Int.* 98(3):717-731 (2020).

105) Schmid-Mohler G, Beckmann S, Zala P, Huber L, Held U, **Fehr T,** Wüthrich RP, Petry H, Mueller TF. First Testing of Literature-Based Models for Predicting Increase in Body Weight and Adipose Tissue Mass After Kidney Transplantation. *Prog Transplant.* 32(4):300-308 (2022)

106) Impact of the COVID-19 pandemic on emergency outpatient consultations and admissions of non-COVID-19 patients (ECCO)-A cross-sectional study. Hangartner N, Di Gangi S, Elbl C, Senn O, Bisatz F, **Fehr T.** *PLoS One.* 17(6):e0269724 (2022)

107) **Fehr T,** Hübel K, de Rougemont O, Abela I, Gaspert A, Güngör T, Hauri M, Helmchen B, Linsenmeier C, Müller T, Nilsson J, Riesterer O, Scandling JD, Schanz U, Cippà PE. Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings. *Front Immunol.* 13:796456 (2022)

108) Sasaki H, Hirose T, Oura T, Otsuka R, Rosales I, Ma D, Lassiter G, Karadagi A, Tomosugi T, Dehnadi A, Matsunami M, Raju Paul S, Reeves PM, Hanekamp I, Schwartz S, Colvin RB, Lee H, Spitzer TR, Cosimi AB, Cippà PE, **Fehr T,** Kawai T. Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates. *Sci Transl Med.* 15(690):eadd5318 (2023)

109) Schwab S, Sidler D, Haidar F, Kuhn C, Schaub S, Koller M, Mellac K, Stürzinger U, Tischhauser B, Binet I, Golshayan D, Müller T, Elmer A, Franscini N, Krügel N, **Fehr T,** Immer F; Swisstransplant Kidney Working Group (STAN); Swiss Transplant Cohort Study. Clinical prediction model for prognosis in kidney transplant recipients (KIDMO): study protocol. *Diagn Progn Res.* 7(1):6 (2023)

110) Katonai Z, Gupta R, Heuss S, **Fehr T,** Ebneter M, Maier T, Meier T, Bux D, Thackaberry J, Schneeberger AR. Serious Games and Gamification: Health Care Workers' Experience, Attitudes, and Knowledge. *Acad Psychiatry*. 47(2):169-173 (2023)

111) Schmucki K, Gaisl T, Hofmann P, Hage R, Steinack C, **Fehr TH,** Ulrich S, Schuurmans MM. mTOR inhibitors after lung transplantation: a real-life experience. *J Thorac Dis.* 16(5):3007-3018 (2024)

112) Brouwers S, Heimgartner R, Laptseva N, Aguzzi A, Ehl NF, **Fehr T**, Hitz F, Jung HH, Kälin J, Manz MG, Müllhaupt B, Ruschitzka F, Seeger H, Stussi G, Zweier M, Flammer AJ, Gerber B, Schwotzer R. Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry. *Swiss Med Wkly.* 154:3485 (2024)

113) Manuel O, Laager M, Hirzel C, Neofytos D, Walti LN, Hoenger G, Binet I, Schnyder A, Stampf S, Koller M, Mombelli M, Kim MJ, Hoffmann M, Koenig K, Hess C, Burgener AV, Cippà PE, Hübel K, Mueller TF, Sidler D, Dahdal S, Suter-Riniker F, Villard J, Zbinden A, Pantaleo G, Semmo N, Hadaya K, Enríquez N, Meylan PR, Froissart M, Golshayan D, **Fehr T,** Huynh-Do U, Pascual M, van Delden C, Hirsch HH, Jüni P, Mueller NJ; Swiss Transplant Cohort Study (STCS). Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial. *Clin Infect Dis*.78(2):312-323 (2024)

114) Ma L, Hao M, Chang W, Deng X, Sun J, Azar MM, Cusini A, **Fehr T,** Gianella S, Goto N, Helweg-Larsen J, Handley G, Hirzel C, Huang L, Konrad R, Mueller NJ, Oka S, Pan L, Peng L, Rostved AA, Sassi M, Sing A, Spielman B, Walsh LF, Wang Y, Yazaki H, Hedstrom L, Imamichi T, Kovacs JA. Unanticipated Global Emergence of Multiple Pneumocystis jirovecii Mutants Selected by Mycophenolic Acid Driving Increasing Outbreaks in Solid Organ Transplant Recipients. *medRxiv* [Preprint]. 2025.06.17.25328583. (2025)

Case Reports

115) **Fehr**,T., Rickli,H., Muller,J., Wuthrich,R.P., & Ammann,P. Kidney at risk: 11-year course of renal artery stenosis. Nephrol. Dial. Transplant. 18, 443-444 (2003).

116) **Fehr**,T., Jacky,E., & Bachli,E.B. Successful reintroduction of methotrexate after acute pneumonitis in a patient with acute lymphoblastic leukemia. Ann. Hematol. 82, 193-196 (2003).

117) Maeder,M., **Fehr**,**T**., August,B., & Galeazzi,R.L. Schwere Hypokaliämie mit Pseudo-QTc Verlängerung. Schweiz. Med. Forum 44, 1066-1067 (2003)

118) **Fehr**,**T**., Zimmermann,D.R., Wuthrich,R.P., & Ammann,P. A young renal transplant recipient with unexplained resting sinus tachycardia, hypertension and beta-blocker resistance. Nephrol. Dial. Transplant. 19, 1646-1649 (2004).

119) Staub-Zahner T, Garzoni D, Fretz C, Lampert C, Ohlschlegel C, Wuthrich RP, **Fehr T**. Pseudotumor of gout in the patella of a kidney transplant recipient. Nat Clin Pract Nephrol. 3, 345-349 (2007).

120) Trachsler J, Gaspert A, Previsdomini M, Wüthric RP, **Fehr T**. Massive uric acid nephrolithiasis with progressive renal failure due to spontaneous tumour lysis syndrome. Nephrol. Dial. Transplant. PLUS 5:307-309 (2008)

121) Gaspert A, Lüthi B, Mueller NJ, Bossart W, Heim A, Wüthrich RP, **Fehr T**. Subacute allograft dysfunction with dysuria and hematuria in a kidney transplant recipient. *Am J Kid Dis.* 54:154-158 (2009)

122) Mülller NJ, Weisser M, **Fehr T**, Wüthrich RP, Müllhaupt B, Lehmann R, Imhof A, Aubert JD, Genoni M, Kunz R, Weber M, Steiger J. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. *Transpl Infect Dis* 12: 54-69 (2010)

123) Cusini A, Günthard HF, Stussi G, Schwarz U, **Fehr T**, Grueter E, Meerbach A, Bossart W, Schaer DJ, Rudiger A. Hemophagocytic syndrome caused by primary herpes simplex virus 1 infection: report of a first case. *Infection* 38: 423-6. (2010)

124) Breitenstein A, Stumpe KDN, Gannt R, **Fehr T,** Etter C. Calcineurin-inhibitor pain syndrome after kidney transplnatation - a rare but disabling condition. *NDT Plus* (2010)

125) Reser D, Tavakoli R, **Fehr T**. Erste schweizerische zweizeitige Herz-Nieren-Transplantation mit Organen desselben Donors. *Schweiz Med Forum* 10: 670–672 (2010)

126) Fritschi BC, Trachsler J, Varga Z, Binet I, **Fehr T**. Iatrogenic nephrocalcinosis with acute renal failure: an underestimated complication after parathyroidectomy? *NDT Plus* (2010).

127) Schleich A, **Fehr T,** Gaspert A, Wüthrich RP, Mohebbi N. Unexpected deterioration of graft function after combined kidney and pancreas transplantation. *Clin Kidney J.* 6, 228-230 (2013)

128) Cippà PE, Gaspert A, Etter C, Guenduez Z, Ferrari-Lacraz S, Rüsi B, **Fehr T**. Late antibody-mediated rejection by de novo donor HLA-DP-specific antibody after renal transplantation: a case report. *Hum Immunol.* 75: 462-5 (2014).

129) Schweizer L, Fischer N, **Fehr T,** Schneiter S. Necrotising coronaritis with fatal outcome. *BMJ Case Rep.* 2017- 219489 (2017).

130) Cattaneo M, Mazzucchelli L, Rüsi-Elsener B, **Fehr T,** Gallino A. Long-term survival after heart transplantation. *Cardiovasc Med* 20: 210-212 (2017).

131) Orlik L, Venzin R, **Fehr T,** Hohloch K. Cerebral salt wasting in a patient with myeloproliferative neoplasm. *BMC Neurol.* 19(1):169. (2019).

132) Vögelin M, Cathomas R, Kamber N, **Fehr T.** Hypokalaemic metabolic alkalosis, hypertension and diabetes: what is the link? *BMJ Case Rep.* 12(1) (2019)

133) Herda C, Steck SM, **Fehr T,** Camartin C. Often Only a Side Event, but Sometimes Groundbreaking - an Ectopic ACTH Secretion as an Example of a Paraneoplastic Syndrome. *Praxis (Bern 1994)* 109(7):517-519 (2020)

134) Szajek K, Kajdi ME, Luyckx VA, **Fehr T,** Gaspert A, Cusini A, Hohloch K, Grosse P. Granulomatous interstitial nephritis in a patient with SARS-CoV-2 infection. *BMC Nephrol.* 8;22(1):19 (2021)

135) Scherer P, Saba K, Strebel R, Gaspert A, Cathomas R, **Fehr T.** Paraneoplastic tubulointerstitial nephritis exacerbated by immune checkpoint inhibitor. *J Onco-Nephrol* 1-5 (2021)

136) Vogel TCE, Schneiter S, **Fehr T.** Peripartum cardiomyopathy: a rare cause of acute heart failure. *BMJ Case Rep.* 15(11):e244821 (2022)

137) Sutter T, **Fehr T,** Blume C, Kajdi ME. Stillbirth and fulminant postpartum haemolysis: COVID-19 or leptospirosis or both? *BMJ Case Rep.* 16(6):e252620 (2023)

138) Kubatzki S, **Fehr** T, Kamber N, Dürst L. Derangierte Elektrolyte. *Schweiz Med Forum* 21:256-259 (2024)

139) Umbricht F, Szajek K, **Fehr T.** Unklarer Status epilepticus. *Schweiz Med Forum* 24:386-388 (2024)

140) Gerber JS, De Marchi S, Gaspert A, **Fehr T,** Cippà PE. JC Polyomavirus Nephropathy: A Rare Complication Late after Kidney Transplantation. *Case Rep Nephrol Dial.* 14(1):148-157 (2024)

141) Drozdz W, Joller D, Grosse P, **Fehr T.** *BMJ Case Rep.*17(9):e258400. Severe lupus nephritis in a young adult with PTEN hamartoma tumour syndrome. (2024)

142) Schnoz C, Bonani M, Huber FA, Helmchen BM, **Fehr T,** Bode-Lesniewska B, Pauli C, Gaspert A. Perinephric myxoid pseudotumor of fat - histopathological and molecular characterization of 3 cases after renal transplantation. *Diagn Pathol.* 20(1):25. (2025)

Reviews and CME

143) **Fehr** T Cholesterinembolien. *Cardiovasc* 2, 52-59 (2003).

144) Maeder M., Klein M., **Fehr** T, & Rickli H. Contrast nephropathy: review focusing on prevention. *J. Am. Coll. Cardiol.* 44, 1763-1771 (2004).

145) **Fehr**,T. & Sykes,M. Tolerance induction in clinical transplantation. *Transpl. Immunol.* 13, 117-130 (2004).

146) Maeder,M., **Fehr**,T., Rickli,H., & Ammann P. Sepsis-associated Myocardial Dysfunction: Diagnostic and Prognostic Impact of Cardiac Troponins and Natriuretic Peptides. *Chest* 129, 1349-1366 (2006).

147) **Fehr**,T., Gaspert,A., Varga,Z., Bosshard,A., & Ambühl,P.M. Hepatitis B- und -C-assoziierte Glomerulonephritiden. *Der Nephrologe* 2, 37-43 (2007).

148) **Fehr**,T. & Sykes,M. Clinical experience with mixed chimerism to induce transplantation tolerance. *Transpl Int* 21, 1118-1135 (2008).

149) **Fehr** T, Wüthrich RP. Monoklonale Antikörpertherapie bei der Organtransplantation. *Schweiz Med Forum* 8:204–209 (2008)

150) Wüthrich RP, **Fehr** T. Probleme nach Nierentransplantation: Ein Drittel der Todesfälle geht auf kardiovaskuläre Komplikationen zurück. *Cardiovasc* 1, 8-12 (2008)

151) Elke B, Ludin S, **Fehr** T. Proteinurie. *Praxis (Bern 1994)* 97:811-818 (2008)

152) Elke B, Ludin S, **Fehr T**. Mikro- und Makrohämaturie bei Erwachsenen. Praxis (Bern 1994) 97:755-761 (2008)

153) Elke B, Gaspert A, **Fehr** T. Akute/Subakute Niereninsuffizienz. *Praxis (Bern 1994)* 97:1057-1066 (2008)

154) Bonani M, **Fehr T**. Chronische Niereninsuffizienz in der Hausarztpraxis. Praxis (Bern 1994) 98:823-832 (2009)

155) Cippà PE, **Fehr T**. Medikamentös induzierte Niereninsuffizienz - Wenn Arzneien an die Nieren gehen. *Hausarzt Praxis* 10:12-14 (2010)

156) **Fehr T**, Stussi G. ABO-incompatible kidney transplantation. Curr Opin Organ Transplant. 17(4):376-85 (2012)

157) **Fehr T,** Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. *Transpl Int.* 25(6):623-32 (2012).

158) Cippà PE, **Fehr T**, Gaspert A, Georgi A. Medikamenten-induzierte akute interstitielle Nephritis. *Praxis (Bern 1994)* 103:865-72 (2014)

159) Hadaya K, **Fehr T**, Rüsi B, Ferrari-Lacraz S, Jean V, Ferrari P. Kidney paired donation: a plea for a Swiss National Programme. *Swiss Med Wkly.* 145:w14083 (2015).

160) **Fehr T,** Cippà PE, Mueller NJ. Cytomegalovirus post kidney transplantation: prophylaxis versus pre-emptive therapy? *Transpl Int.* 28:1351-6 (2015).

161) Seeger H, **Fehr T**. [Nephrotic Syndrome in Adult Patients--Etiology and Complications]. *Praxis (Bern 1994).* 105:259-67 (2016).

162) Klein HJ, Schanz U, Hivelin M, Waldner M, Koljonen V, Guggenheim M, Giovanoli P, Gorantla VS, **Fehr T**, Plock JA. Sensitization and desensitization of burn patients as potential candidates for vascularized composite allotransplantation. *Burns* 42(2):246-57 (2016)

163) Cippà PE, **Fehr T**. Pharmacological modulation of cell death in organ transplantation. *Transpl Int.* 30:851-859 (2017)

164) Thalmann G, Hausammann R, **Fehr T,** Albert S. [CME - Transient Global Amnesia]. *Praxis (Bern 1994)* 106:1315-1322 (2017)

165) Glück M, Locher R, **Fehr T.** [CME: Hypocalcemia]. *Praxis (Bern 1994)* 107:353-359 (2018)

166) Platzer S, **Fehr T,** Latshang T. CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma. *Praxis (Bern 1994).* 107:1129-1135 (2018)

167) **Fehr T.** Nephroprotektion - endlich ein Forschritt! *Hausarzt Praxis* 13: 1-5 (2018)

168) Gund SM, **Fehr T,** Camartin C. CME: Dehydration and Artificial Hydration for Terminally Ill Patients. *Praxis (Bern 1994)* 108(1):9-16 (2019).

169) Reiner K, **Fehr T,** Wick J. CME: Giant Cell Arteritis. *Praxis (Bern 1994)* 110(6):285-292 (2021)

170) Fiore V, Rakusa J, **Fehr T,** Wick J. CME: Musculoskeletal Manifestations of Lyme Disease. *Praxis (Bern 1994)* 110(5):231-236 (2021)

171) **Fehr T**. Hyperurikämie, Gicht und chronische Niereninsuffizienz. *Rheuma Schweiz* 4, 40-47 (2021)

172) **Fehr T**, Camartin C. Schmerzmittel und Niere - Empfehlungen für die Praxis. Rheuma Schweiz 4, 48-53 (2021)

173) Sutter T, **Fehr T,** Venzin R. [CME: Diagnostic Approach and Management of Thrombotic Microangiopathy]. *Praxis (Bern 1994).* 111(14):771-777 (2022)

174) Iven-Assmann L, Szajek K, Sturzenegger R, Cusini A, **Fehr T.** [CME: Neuroborreliosis]. *Praxis (Bern 1994).* 111(14):779-787 (2022)

175) Schmucki K, Hofmann P, **Fehr T,** Inci I, Kohler M, Schuurmans MM. Mammalian Target of Rapamycin Inhibitors and Kidney Function After Thoracic Transplantation: A Systematic Review and Recommendations for Management of Lung Transplant Recipients. *Transplantation* 107(1):53-73 (2023)

176) **Fehr T,** Gaspert A. AA Amyloidose und Niere. *Rheuma Schweiz* 4: 42-46(2024)

177) Spotswood G, Dürst L, **Fehr T,** Rogalla von Bieberstein L. [Paraneoplastic limbic encephalitis - an important differential diagnosis in cases of unclear encephalopathy]. *Praxis (Bern 1994)*114(6):234-239 (2025)

Editorials, commentaries and recommendations

178) Ammann,P., Pfisterer,M., **Fehr,T**., & Rickli,H. Raised cardiac troponins (Editorial). BMJ 328, 1028-1029 (2004)

179) **Fehr T,** Ambuhl PM. Chronic hepatitis virus infections in patients on renal replacement therapy (Editorial). *Nephrol. Dial. Transplant.* 19, 1049-1053 (2004)

180) **Fehr,T.** & Ochsenbein,A.F. Outcome of the antibody response: a question of antigen dose and distribution. *Trends Immunol.* 25, 165-166 (2004)

181) **Fehr T,** Bardwell P, Sykes,M. Commentary on „Use of skin grafting to demonstrate tolerance before kidney transplantation without immunosuppressio

182) Cippà PE, **Fehr T** Spontaneous tolerance in kidney transplantation--an instructive, but very rare paradigm. *Transpl Int.* 24: 534-5 (2011)

183) van Gelder T; ESOT Advisory Committee on Generic Substitution. European Society for Organ Transplantation Advisory Committee recommendations on generic substitution of immunosuppressive drugs. *Transpl Int.* 24: 1135-41 (2011)

184) **Fehr T,** Cohen CD. Predicting an allograft's fate. *Kidney Int.* 80: 1254-5 (2011)

185) **Fehr T.** Rheuma und Organtransplantation. *Rheuma Schweiz.* 1: 36-40 (2013)

186) **Fehr T,** Immer F. Marginal organ allocation: old and new REALity. *Transpl Int.* 30:1212-1214 (2017)

187) **Fehr T.** Post-transplant lymphoproliferative disorder prevention: new light on the horizon? *Transpl Int.*31:478-480 (2018)

188) **Fehr T.** Elderly kidney donors: better than their reputation-but where are the limits? *Transpl Int.* 31:700-702 (2018)

189) Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, **Fehr T,** Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. *Swiss Med Wkly.* 150:w20364 (2020)

190) Condoluci A, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M, Bacher U, Bode P, Cavalli A, Dirnhofer S, Djerbi N, Dobner S, **Fehr T,** Garofalo M, Gaspert A, Gerull S, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Magini G, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pabst T, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Treglia G, Tzankov A, Vetter F, Zweier M, Flammer AJ, Gerber B. SAN recommendations for the management of transthyretin amyloidosis. *Swiss Med Wkly* 151:w30053 (2021).

191) Rieger MJ, Flammer AJ, Gerull S, Pabst T, Auner HW, Samii K, Hitz F, Mey U, Ballova V, Battegay R, Melli G, Benz D, Yakupoglu Y, Gräni C, Schläger R, Hugelshofer S, Studer A, Oechslin L, Bakula A, Suter TM, LeoStickelberger J, Averiamo M, **Fehr T,** Jung HH, Laptseva N, Manka R, Rüfer A, Schmidt A, Seeger H, Müllhaupt B, Stämpfli SF, De Ramon Ortiz C, Théaudin M, Gerber B, Schwotzer R. Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network. *Swiss Med Wkly* 155:4219 (2025)

192) Hofmann P, Risch M, **Fehr T.** Albumin-corrected calcium. *Praxis (Bern 1994)* 114(1):42-44. (2025)

Book chapters

193) **Fehr**,**T**. & Wüthrich,R.P. Wasser-, Elektrolyt- und Säure/Basestörungen in Differenzialdiagnose Innerer Krankheiten, Edn. 19. ed. Siegenthaler,W. 902-955 (Thieme Verlag, 2005).

194) **Fehr**,**T**. & Wüthrich,R.P. Water, electrolyte and acid-base disorders in Differential diagnosis in Internal Medicine, Edn. 19. ed. Siegenthaler,W. (Thieme edition, 2007).

195) **Fehr,T.** & Wüthrich,R.P. Wasser-, Elektrolyt- und Säure/Basestörungen in Differenzialdiagnose Innerer Krankheiten, Edn. 20. ed. Battegay E. 882-940 (Thieme Verlag, 2012)